|
FDA To Hold Public Teleconference on October 16 on Myalgic …
Sacramento Bee Rituximab is also showing promise in trials of ME/CFS patients. “The researchers and clinical experts involved in these studies are some of the top ME/CFS experts in the world and have the experience to know what outcome measures are best for ME/CFS … |
|
Gileads Idelalisib Encourages
Zacks.com Interim analysis of the randomized, double-blind, placebo-controlled study revealed that patients treated with idelalisib plus Roche’s (RHHBY) Rituxan (rituximab) exhibited statistically significant improvement in progression free survival compared to … |
|
From 2012 to 2022, the Rheumatoid Arthritis Market Will Grow Moderately …
The Providence Journal Pfizer/Takeda’s Jak inhibitor Xeljanz will likely be used after the TNF-alpha inhibitors initially, competing with Bristol-Myers Squibb/Ono Pharmaceutical’s Orencia, rituximab (Biogen Idec/Roche/Chugai/Zenyaku Kogyo’s Rituxan, Roche’s MabThera) and … |
StreetInsider.com (subscription)Pre-Open Stock Movers 10/10: (ACUR) (CHTP) (NFLX) Higher; (CTXS) (RT …StreetInsider.com (subscription)This DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficacy …
|
Rituximab Biosimilar Market Opportunity Analyzed in New Research Report at …
PR Web (press release) In this report “Therapy Class Overview: Rituximab biosimilar – http://www.reportsnreports.com/reports/269204-therapy-class-overview-rituximab-biosimilar.html ”, we have analyzed the market opportunity of rituximab biosimilar. What one would get if buy … |
|
Gilead halts leukaemia study on positive results
PMLiVE The trial – known as Study 116 – is comparing idelalisib plus Roche/Biogen Idec’s Rituxan (rituximab) to rituximab alone in patients unsuitable for treatment with conventional chemotherapy. At an interim analysis, the combination was found to have a … Gilead Stops Cancer Drug Trial Early On Positive ResultsNASDAQ UPDATE: Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic …Benzinga Gilead stops leukaemia drug trial earlyPharmaTimes MarketWatch all 21 news articles » |
|
Alethia Biotherapeutics obtains US patent for use of anti-Siglec-15 antibodies
Pharmaceutical Business Review The patent entitled ‘Polynucleotides and Polypeptide Sequences involved in the Process of Bone Remodeling’, provides broad protection for antibodies that target Siglec-15 and also having osteoclast differentiation or bone resorption inhibitory activity. |
|
Gilead stops leukaemia drug trial early
PharmaTimes The safety profile of the drug was also found to be “acceptable and consistent with prior experience” when combing it with rituximab in previously treated CLL. Norbert Bischofberger, Gilead’s R&D chief, said the firm is pleased that idelalisib has … |
|
Heptares’ StaR platform offers breakthrough solution to challenge associated …
News-Medical.net Heptares’ StaR platform offers a breakthrough solution to the main challenge associated with making antibodies against GPCRs: producing purified, properly folded and functional protein when removed from the cell membrane for use as an antigen. Heptares Delivers First Stabilised GPCR (StaR®) to MorphoSys for Antibody …PR Newswire (press release) |
|
Heptares Delivers First Stabilised GPCR (StaR®) to MorphoSys for Antibody …
HispanicBusiness.com The milestone is based on the generation of a stabilised (StaR(R)) form of the first GPCR target selected by MorphoSys, a key step that will enable its use as an antigen against which novel antibodies can be produced. Heptares will receive an … |